SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2012 Biotech Charity Contest
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (429)1/1/2013 9:40:44 PM
From: mcbio  Read Replies (1) of 513
 
On TSRX, I don't view their advantages over future generic Zyvox as "meager." First, they will likely be on the market a year or so before Zyvox goes generic. Second, there are many advantages over Zyvox beyond the QD that you note including much shorter course of therapy (6 days vs. 10), better tolerability, etc. They also have a novel wholly-owned gyrase inhibitor set to enter the clinic in 2013. TSRX just missed the cut-off on my charity picks but I am very much considering a position before the second P3 results come due end of 1Q13/early 2Q13 provided I have the funds.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News